Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12191MR)

This product GTTS-WQ12191MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12191MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13864MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ12171MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ1493MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ8963MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ4940MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ4550MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ6555MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ13026MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW